Animal Models for Preclinical Imaging - Nanotechnology for Biomedical Imaging and Diagnostics - page 473

Treatment of pets is not regulated by the FDA, but is left up to the owners and
attending veterinarians. Use of experimental agents, whether therapeutic or diag-
nostic, is therefore not as restrictive as in humans. Compounds need not be produced
in GMP facilities or be approved for investigational use by the FDA. This does not
mean that agents should not be tested first in rodent models, but that promising agents
may be tested in closer-to-clinic companion animal models to confirm preclinical
test results prior to initiating the very expensive processes required for investigational
new drug (IND).
references
[1] National Research Council. Guide for the Care and Use of Laboratory Animals . 8th ed.
Washington, DC: The National Academies Press; 2011.
[2] Gosens I, Post JA, de la Fonteyne lJ, Jansen EH, Geus JW, Cassee FR, de Jong WH.
Impact of agglomeration state of nano- and submicron sized gold particles on pulmonary
inflammation. Part Fibre Toxicol 2010; 7 :37.
[3] Pai MP. Drug dosing based on weight and body surface area: mathematical assumptions
and limitations in obese adults. Pharmacotherapy 2012; 32 :856-868.
[4] Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and
PET. Nucl Med Biol 2005; 32 :673-678.
[5] Hawk CT, leary Sl, Morris TH, American College of laboratory Animal Medicine.,
and European College of laboratory Animal Medicine. Formulary for Laboratory
Animals . 3rd ed. Ames, IA: Blackwell Publishing; 2005.
[6] Doria AS, Crawley A, Gahunia H, Moineddin R, Rayner T, Tassos V, Zhong A, Pritzker
K, Mendes M, Jong R, Salter RB. Correlative BolD MR imaging of stages of synovitis
in a rabbit model of antigen-induced arthritis. Pediatr Radiol 2012; 42 :63-75.
[7] Wang SX, Arsenault l, Hunziker EB. Stereologic analysis of tibial-plateau cartilage and
femoral cancellous bone in guinea pigs with spontaneous osteoarthritis. Clin orthop
Relat Res 2011; 469 :2796-2805.
[8] Guingamp C, Gegout-Pottie P, Philippe l, Terlain B, Netter P, Gillet P. Mono-
iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of
mobility, morphology, and biochemistry. Arthritis Rheum 1997; 40 :1670-1679.
[9] Siebelt M, Waarsing JH, Kops N, Piscaer TM, Verhaar JA, oei EH, Weinans H.
Quantifying osteoarthritic cartilage changes accurately using in vivo microCT arthrogra-
phy in three etiologically distinct rat models. J orthop Res 2011; 29 :1788-1794.
[10] Almarestani l, Fitzcharles MA, Bennett GJ, Ribeiro-da-Silva A. Imaging studies in
Freund's complete adjuvant model of regional polyarthritis, a model suitable for the
study of pain mechanisms, in the rat. Arthritis Rheum 2011; 63 :1573-1581.
[11] Irmler IM, opfermann T, Gebhardt P, Gajda M, Brauer R, Saluz HP, Kamradt T. In vivo
molecular imaging of experimental joint inflammation by combined (18)F-FDG positron
emission tomography and computed tomography. Arthritis Res Ther 2010; 12 :R203.
[12] Caglic D, Globisch A, Kindermann M, lim NH, Jeske V, Juretschke HP, Bartnik E,
Weithmann KU, Nagase H, Turk B, Wendt KU. Functional in vivo imaging of cysteine
cathepsin activity in murine model of inflammation. Bioorg Med Chem 2011; 19 :
1055-1061.